MyAbilities Technologies, a company involved in smart health technology and workplace safety, has launched what is claimed to be the world's first online Digital Job Analysis database, JobXweb.com, it was reported yesterday.
The free database offers users access to more than 50,000 job titles, each with unique industry Digital Job Profiles including comprehensive analysis of the psychosocial, cognitive and physical demands in addition to a comprehensive job description. Each Digital Job Profile includes the essential demands of that job, whether they are physical, cognitive or psychosocial. Digital Job Profiles are shared with various stakeholders to support decisions leveraging the exact same set of data in a standardised, visual way to understand all the demands of the job.
Dr Michael Sonne, vice president, innovations and research at MyAbilities Technologies, said, 'Organisations can quickly search through a simple and free database to conduct a thorough review of the demands of thousands of jobs across all industries. We believe JobXweb.com is the first of its kind to offer easy access to a standardised analysis of thousands of jobs, and to present the information in a clear, shareable way.'
FDA grants priority review to Takeda's zasocitinib application for plaque psoriasis
Armata Pharmaceuticals announces receipt of FDA Breakthrough Therapy Designation for AP-SA02
AstraZeneca's Etcamah misses primary endpoint in Phase III breast cancer trial
GSK reports positive Jideytro data supporting potential first-line lung cancer use
Akeso presents positive results from registrational Phase III study of ivonescimab
FDA grants Priority Review to Genentech's Enspryng for MOGAD
Seismic Pharmaceuticals enrols first patient in istaroxime global Phase 3 trial in cardiogenic shock
BioEdge Research Labs advances transparency in research compound documentation
Insilico Medicine doses first patient in Phase III trial of rentosertib
BridgeBio reports exploratory PROPEL 3 data showing wider clinical trends for oral infigratinib
Tyra Biosciences declares positive Phase 2 results for oral dabogratinib in bladder cancer
Harbour BioMed partner raises USD225m to advance neoadjuvant immuno-oncology therapy porustobart
Kazia Therapeutics doses first patient in paediatric AT/RT study